Octagon Capital Advisors’s Celldex Therapeutics CLDX Stock Holding History

Octagon Capital Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-707,526	Closed	-$28.1M	–	59
2023 Q4	$28.1M	Sell	707,526 -52,372	-7%	-$1.54M	4.49%	7
2023 Q3	$20.9M	Hold	759,898	–	–	3.21%	11
2023 Q2	$25.8M	Hold	759,898	–	–	3.59%	7
2023 Q1	$27.3M	Sell	759,898 -1,500	-0.2%	-$64.7K	3.93%	9
2022 Q4	$33.9M	Hold	761,398	–	–	5.28%	6
2022 Q3	$21.4M	Hold	761,398	–	–	3.69%	7
2022 Q2	$20.5M	Hold	761,398	–	–	5.48%	6
2022 Q1	$25.9M	Hold	761,398	–	–	5.61%	3
2021 Q4	$29.4M	Hold	761,398	–	–	5.73%	6
2021 Q3	$41.1M	Buy	761,398 +200,000	+36%	+$9.38M	10.12%	3
2021 Q2	$18.8M	Hold	561,398	–	–	3.89%	8
2021 Q1	$11.6M	Sell	561,398 -480,000	-46%	-$11M	4.36%	8
2020 Q4	$18.2M	Buy	+1,041,398	New	+$18.7M	6.32%	3

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Octagon Capital Advisors's CLDX Position: Q1 2024 in Review

Octagon Capital Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2024, closing a stake of 707,526 shares — an estimated $28.1M sold.

Octagon Capital Advisors first reported a position in CLDX in Q4 2020 and held it in 13 quarters. The position peaked at $41.1M in Q3 2021. 197 funds tracked by Wall St. Rank hold CLDX as of Q1 2024.

Octagon Capital Advisors reported no remaining Celldex Therapeutics position as of Q1 2024 after selling out during the quarter.
Octagon Capital Advisors sold 707,526 Celldex Therapeutics shares in Q1 2024, an estimated $28.1M.
Octagon Capital Advisors first reported a position in Celldex Therapeutics in Q4 2020 and held it in 13 quarters.
Octagon Capital Advisors's Celldex Therapeutics position peaked at $41.1M in Q3 2021.
197 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2024.

Based on Octagon Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.